重组人血管内皮抑制素(恩度)临床机制的研究进展  

Advance in the Clinical Mechanism of Recombinant Human Endostatin

作　　者：韩楠楠 姜秋颖[1] 李里[1] 滕冲[1] 吕艳菊[1] HAN Nan-nan;JIANG Qiu-ying;LI Li;TENG Chong;LV Yan-ju(The second affiliated hospital of Harbin medical university,Heilongjiang,150000,China)

机构地区：[1]哈尔滨医科大学附属第二医院肿瘤内科

出　　处：《现代生物医学进展》2019年第15期2993-2995,共3页Progress in Modern Biomedicine

基　　金：国家自然科学基金面上项目(81702464)

摘　　要：重组人血管内皮抑制素(Endostar,恩度)是由我国科学家自主研发的血管内皮抑制素类抗肿瘤药物,是一种大肠杆菌工程菌发酵产品,在临床上常被用作血管靶向治疗,具有靶向精准、低毒性、不产生耐药等优点。恩度能够抗血管生成、诱导肿瘤细胞凋亡,然而只应用抗血管生成药物治疗肿瘤患者,并不能使其得到明显的生存获益,恩度联合化疗/放疗具有增敏作用,从而取得显著的疗效。本文对恩度的作用机制进行探讨,以便于为更好的应用于临床提供有益的参考信息。Recombinant human endostatin(Endostar) is an endostatin-based antitumor drugs developed independently by Chinese scientists. It is a fermentative product of escherichia coli engineering bacteria and is often used clinically as a vascular targeted therapy,with the advantages of targeted precision, low toxicity, not producing resistance and so on. Endostar is capable of anti-angiogenesis and inducing apoptosis of tumor cells;however, only the application of anti-angiogenic drugs in the treatment of patients with cancer is not able to make them gain significant survival benefit. Endostar combined with chemotherapy/radiotherapy has a sensitizing effect, so as to achieve a one-plus-one-is-greater-than-two effect. This article discusses the mechanism of Endostar, in order to better apply to clinic.

关 键 词：重组人血管内皮抑素 恩度 抗血管生成 凋亡 增敏 

分 类 号：R730.5[医药卫生—肿瘤] R979.1[医药卫生—临床医学]